Leukemia Clinical Trial
Official title:
A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
The goal of this clinical research study is to learn how PCI-32765 (ibrutinib) may affect the
life cycle of blood-cancer cells. Cancer cells will be "labeled" with heavy water to learn
about their birth rates and death rates.
Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that
help cells live and grow. The study drug is designed to inhibit or "block" the activity of a
type of kinase that helps blood-cancer cells live and grow. By blocking the activity of this
specific kinase, it is possible that the study drug may kill the cancer cells or stop them
from growing.
Heavy water (2H2O) is a special type of water that is designed to help researchers learn how
quickly cancer cells in the body reproduce.
Heavy Water Administration:
If you are found to be eligible to take part in this study, you will receive heavy water to
drink for 4 weeks. The vials of heavy water will be shipped to your home location.
On Days 1-5, you will drink the heavy water 3 times each day. You will drink 1 dose in the
morning, 1 dose in the afternoon, and 1 dose in the evening. You should take the doses at
least 3 hours apart. If you miss a dose, take it as soon as you remember. Make sure to wait
at least 3 hours between doses.
Starting on Day 6 and until your first study visit, you will drink the heavy water 1 time
each day in the evening.
You may choose to drink the heavy water with or without food.
You will be given a study diary to record your doses. If you miss a dose, take it as soon as
you remember. If you vomit a dose, you do not need to make it up. Just wait until the next
regularly scheduled dose and make a note of it in the diary.
Heavy Water Study Visits:
On Day 1 and during Weeks 2 and 4, blood (about 5 tablespoons) will be drawn for routine
tests and for heavy water testing. These blood samples will not be banked for future
research. The samples will only be used for research in this study and will be kept until all
DNA and protein analysis is complete. These Samples will be sent to our collaborators at the
Feinstein Institute for Medical Research and KineMed, Inc., in order to conduct the heavy
water analyses.
After Week 4, you will stop drinking the heavy water and will be followed either in the
clinic or by your local doctor for 6-12 weeks.
Every 2 weeks during the time after you stop drinking heavy water and before you start taking
ibrutinib, the following tests and procedures will be performed:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 4 tablespoons) will be drawn for heavy water testing. This measures how
fast the cancer cells are making new protein and DNA.
- You will be asked about any drugs you may be taking.
Every 4 weeks during the time after you stop drinking heavy water and before you start taking
ibrutinib, blood (about 1 tablespoon) will be drawn for routine tests.
Ibrutinib Administration:
Beginning around Weeks 10-16, you will start taking ibrutinib. You will take 3 capsules by
mouth with 1 cup (8 ounces) of water 1 time a day. The dose should be taken at least 30
minutes before eating and at least 2 hours after a meal, at about the same time each day.
If you miss or vomit a dose, do not make up the dose. Take the next dose at your regularly
scheduled time and be sure to write it down in the study diary.
You will take the study drug for up to 12 cycles. Each cycle is 28 days. If the doctor thinks
it is in your best interest, you may continue taking the study drug even after 12 cycles.
You will also take allopurinol by mouth 1 time each day during the first 1-2 weeks of taking
ibrutinib to lower the risk of side effects.
Ibrutinib Study Visits:
At every study visit, you will be asked about any drugs you may be taking and about any side
effects you may be having.
On Days 1 and 3 of Week 1, and at the end of Weeks 2, 4, 6, 8, and 10:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Blood (about 4 tablespoons) will be drawn for heavy water testing.
At the end of Week 12:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Blood (about 4 tablespoons) will be drawn for heavy water testing.
- You will have computed tomography (CT) scans of the chest, abdomen, and pelvis to check
the status of the disease.
- You will have a bone marrow aspiration to check the status of the disease. To collect a
bone marrow aspirate, an area of the hip or other site is numbed with anesthetic, and a
small amount of bone marrow is withdrawn through a large needle.
At the end of Weeks 16 and 20:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 2 tablespoon) will be drawn for routine tests.
At the end of Weeks 24 and 36:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have CT scans to check the status of the disease.
- You will have a bone marrow aspiration to check the status of the disease.
At the end of Week 48:
- You will have a physical exam, including measurement of your vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have CT scans to check the status of the disease.
Length of Study Drug Dosing:
You may continue taking the study drug for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drug if the disease gets worse, if
intolerable side effects occur, or if you are unable to follow study directions.
Your participation on the study will be over after the end-of-study visits.
Follow-Up Visi:
If you continue taking the study drug past 12 cycles, you will come to the clinic for
follow-up visits every month. You will continue to have follow-up visits as long as you are
taking the study drug. At each visit, the following tests and procedures will be performed:
You will have a physical exam, including measurement of you vital signs. Blood (about 1
tablespoon) will be drawn for routine tests.
Whenever the doctor thinks it is needed, you will have the following tests and procedures:
You may have CT scans to check the status of the disease. You may have a bone marrow
aspiration to check the status of the disease.
End-of-Study Visits:
After your last dose of study drug, and then 1 more time during the next month, you will have
end-of-study visits. The following tests and procedures will be performed:
You will have a physical exam, including measurement of you vital signs. You will be asked
about any symptoms you may be having. Blood (about 1 tablespoon) will be drawn for routine
tests.
This is an investigational study. Ibrutinib is FDA approved and commercially available for
the treatment of patients with mantle cell lymphoma. Its use in this study is
investigational.
Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |